Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +35

AIA Group Ltd Raises Stake in Biogen Inc. $BIIB - Defense World

📈 AIA Group Ltd increased its Biogen stake by 310.1% in Q1, adding 7,054 shares to a total holding of 9,329 shares valued at $1.71 million.

🏦 Rothschild Investment LLC boosted holdings by 12.3%, while Itau Unibanco Holding S.A. increased its position by 24.4% in the fourth quarter.

📉 HSBC reiterated a 'reduce' rating with a $157.00 price objective, and Zacks Research downgraded the stock to a 'strong sell' rating.

📈 Truist Financial upgraded Biogen to a 'buy' rating with a new price target of $235.00, signaling potential upside.

🏛️ UBS Group upgraded its rating to 'buy' and raised the price target to $225.00 in an April report.

💰 Goldman Sachs increased its price objective to $238.00 and assigned a 'buy' rating in late April.

📊 The consensus analyst rating is 'Moderate Buy' with a collective price target of $220.04 according to MarketBeat data.

💵 Biogen Inc. has a market capitalization of $30.41 billion and trades at a PE ratio of 22.10.

📉 The stock currently trades between a twelve-month low of $121.05 and a high of $219.72.

🛡️ Biogen maintains strong liquidity with a current ratio of 3.06 and a quick ratio of 2.41.

🧬 The company focuses on therapies for neurological conditions including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

📈 Institutional ownership stands at approximately 87.93% of the company's total stock.

Bullish Signals
  • AIA Group Ltd significantly increased its stake in Biogen by 310.1% in Q1, adding 7,054 shares to a total holding of 9,329 shares valued at $1.71 million.
  • Rothschild Investment LLC boosted its holdings by 12.3%, while Itau Unibanco Holding S.A. increased its position by 24.4% in the fourth quarter.
  • Truist Financial upgraded Biogen to a 'buy' rating with a new price target of $235.00, indicating analyst confidence in future performance.
  • UBS Group upgraded its rating to 'buy' and raised the price target to $225.00 in an April report.
  • Goldman Sachs increased its price objective to $238.00 and assigned a 'buy' rating in late April.
  • The consensus analyst rating is 'Moderate Buy' with a collective price target of $220.04 according to MarketBeat data.
  • Biogen maintains strong liquidity with a current ratio of 3.06 and a quick ratio of 2.41, suggesting financial stability.
  • The company has a low debt-to-equity ratio of 0.34, indicating manageable leverage relative to its equity base.
Risk Factors
  • HSBC reiterated a 'reduce' rating with a $157.00 price objective, which is significantly below the current trading price.
  • Zacks Research downgraded Biogen to a 'strong sell' rating in late June, reflecting bearish sentiment among some analysts.
  • The stock has experienced significant volatility, trading between a twelve-month low of $121.05 and a high of $219.72.
Full Analysis
AIA Group Ltd significantly increased its stake in Biogen Inc. (NASDAQ: BIIB) by 310.1% during the first quarter, acquiring an additional 7,054 shares to hold a total of 9,329 shares valued at $1.71 million. Several other institutional investors also adjusted their positions, with Rothschild Investment LLC boosting holdings by 12.3%, Kera Capital Partners Inc. increasing theirs by 3.5%, and Itau Unibanco Holding S.A. raising its stake by 24.4%. Collectively, hedge funds and institutional investors own approximately 87.93% of the company's outstanding stock. Analyst sentiment regarding Biogen remains mixed with conflicting price targets and ratings. HSBC reiterated a 'reduce' rating with a $157.00 price objective, while Zacks Research downgraded the stock to a 'strong sell.' Conversely, Truist Financial upgraded its rating to 'buy' with a target of $235.00, UBS Group moved to 'buy' with a $225.00 target, and Goldman Sachs raised its objective to $238.00. The consensus rating is currently a 'Moderate Buy' with an average price target of $220.04. Biogen Inc. operates as a multinational biotechnology firm focused on therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Founded in 1978 and headquartered in Cambridge, Massachusetts, the company holds a market capitalization of $30.41 billion with a PE ratio of 22.10. Financial metrics show a current ratio of 3.06, a quick ratio of 2.41, and a debt-to-equity ratio of 0.34, while the stock trades between a twelve-month low of $121.05 and a high of $219.72.